Company intelligence / Profile preview

NSRA

Ownership: Private
Development stage: Other

Overview

NS Pharma focuses on rare diseases with programs targeting neurological and inflammatory conditions. Its lead program has reached regulatory submission stage for Mucopolysaccharidosis II. Another program, NS‑229, received Orphan Drug Designation from the FDA in April 2025 for Eosinophilic Granulomatosis with Polyangiitis. Clinical results are not detailed publicly but regulatory milestones indicate positive progress.

Therapeutic areas: ImmunologyRare Diseases
Modalities: Biologic
Industry: Biotech

Beyond the preview

Go deeper on NSRA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSRA.

Explore the full profile